ReviewJournal of human hypertension2022
Highlights of mechanisms and treatment of obesity-related hypertension.
Review in Journal of human hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.Endocrine · 2026Pooled it
- Impact of physical activity associated with bariatric surgery on systemic arterial hypertension control: a systematic review.Sao Paulo medical journal = Revista paulista de medicina · 2026Pooled it
- Semaglutide and blood pressure: an individual patient data meta-analysis.European heart journal · 2024 · on this mapPooled it
- Trial
- Cancer and Hypertension: Shared Mechanisms, Treatment Interactions, and Clinical Management.Cancer medicine · 2026Review
- Global DNA methylation and hypertension control Vis-À-Vis lipids: an exploratory population based study from rural Punjab, India.Journal of human hypertension · 2026Article
- Female-specific hypertension risk factors across the lifecourse: a co-twin control analysis using the California Twin Program.American journal of epidemiology · 2026Article
- Article
- Nonlinear association between metabolic score for insulin resistance (METS-IR) and prevalent hypertension: a cross-sectional study.BMC cardiovascular disorders · 2026Article
- Diagnostic Accuracy and Clinical Utility of an Ayurvedic Questionnaire for Predicting Metabolic Syndrome.Cureus · 2026Article
- Overcoming variable response in renal denervation: Key strategies for reliable clinical implementation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Intermittent hypoxic conditioning as a novel strategy for obesity treatment: current evidence and future perspectives.Frontiers in physiology · 2026Review
- Impact of Obesity on the Association Between Salt Intake and Blood Pressure in Adult Men With Hypertension Who Participated in the Remote Lifestyle Intervention.Journal of obesity · 2026Observational
- Article
- Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments.Clinical kidney journal · 2025Review
- Diabetes Mellitus and Hyperlipidemia Status Among Hypertensive Patients in the Community and Influencing Factors Analysis of Blood Pressure Control.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Joint Effect of Central Obesity and Family History on Hypertension in Type 2 Diabetes: A Cross-Sectional Study in China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Effects of Maternal Prepregnancy Nutritional Status on Pregnancy Outcomes.Emergency medicine international · 2025Article
- Obesity indices and diabetes risk among hypertensive patients: insights from the China Multi-Ethnicity Cohort study.Frontiers in endocrinology · 2025Article
- Mediating Effects of Serum Lipids and Physical Activity on Hypertension Management of Urban Elderly Residents in China.Metabolites · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of obesity has increased two to three times from 1975 to 2015. Large-scale epidemiological and longitudinal prospective studies link obesity with hypertension. Research suggests that excessive weight gain, particularly when associated with visceral adiposity, may account for as much as 65% to 75% of the risk of incident hypertension. Also, exercise and bariatric/metabolic surgery significantly lowers blood pressure, whereas weight gain increases blood pressure, thus establishing a firm link between these two factors. The mechanisms underpinning obesity-related hypertension are complex and multifaceted, and include, but are not limited to, renin-angiotensin-aldosterone system/sympathetic nervous system overactivation, overstimulation of adipokines, insulin resistance, immune dysfunction, structural/functional renal, cardiac, and adipocyte changes. Though weight loss is the mainstay of treatment for obesity-related hypertension, it is often not a feasible long-term solution. Therefore, it is recommended that aggressive treatment with multiple antihypertensive medications combined with diet and exercise be used to lower blood pressure and prevent complications. The research regarding the mechanisms and treatment of obesity-related hypertension has moved at a blistering pace over the past ten years. Therefore, the purpose of this expert review is two-fold: to discuss the pathophysiological mechanisms underlying obesity-related hypertension, and to revisit pharmacotherapies that have been shown to be efficacious in patients with obesity-related hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.